Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi · 2025
Recurrence of Streptococcus agalactiae bacteremia - risk factors and complications.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Garellek Jonathan A, Wang Taylor, Epstein Marcia, Kim Angela, Zimilover Adam, Gorlin Margaret, Juretschko Stefan, Smith Miriam A
Аннотация
BACKGROUND: This study was undertaken to investigate the incidence and risk factors for Streptococcus agalactiae (GBS) bacteremia recurrence in patients following first episode of GBS bacteremia.
METHODS: This was a retrospective observational study evaluating admitted patients from January 1, 2016 to 12/31/2019. Non-pregnant patients ≥18 years old with GBS bacteremia were included. Recurrence was defined as admission due to GBS bacteremia within 1 year after a positive GBS blood culture.
RESULTS: Nineteen out of 388 patients with GBS bacteremia had recurrence. There was a significant increase in recurrence in patients allergic to β-lactams, in patients with implantable cardiac devices (ICDs), and in patients who did not receive β-lactams or vancomycin as empiric treatment. The estimated odds of recurrence in patients with allergy to β-lactams was 3.1 times the odds of recurrence without allergy after adjusting for ICD status (95 % CI, 1.1-8.9, p < 0.04). The estimated odds for recurrence in patients with ICDs were 5.8 times the odds of patients without ICDs controlling for β-lactam allergy (95 % CI, 1.7-19.9, p < 0.01).
CONCLUSIONS: Our study suggests that GBS bacteremia recurrence is associated with presence of ICDs, β-lactam allergy, and not having received β-lactams or vancomycin as initial treatment.
METHODS: This was a retrospective observational study evaluating admitted patients from January 1, 2016 to 12/31/2019. Non-pregnant patients ≥18 years old with GBS bacteremia were included. Recurrence was defined as admission due to GBS bacteremia within 1 year after a positive GBS blood culture.
RESULTS: Nineteen out of 388 patients with GBS bacteremia had recurrence. There was a significant increase in recurrence in patients allergic to β-lactams, in patients with implantable cardiac devices (ICDs), and in patients who did not receive β-lactams or vancomycin as empiric treatment. The estimated odds of recurrence in patients with allergy to β-lactams was 3.1 times the odds of recurrence without allergy after adjusting for ICD status (95 % CI, 1.1-8.9, p < 0.04). The estimated odds for recurrence in patients with ICDs were 5.8 times the odds of patients without ICDs controlling for β-lactam allergy (95 % CI, 1.7-19.9, p < 0.01).
CONCLUSIONS: Our study suggests that GBS bacteremia recurrence is associated with presence of ICDs, β-lactam allergy, and not having received β-lactams or vancomycin as initial treatment.